# data[].attributes.headline
CARDIOVASCULAR DISEASES AROUND THE WORLD

# data[].attributes.subject
CARDIOVASCULAR DISEASES AROUND THE WORLD

# data[].attributes.body
Cardiovascular disease is taking the lives of millions of people yearly around the world; 17.9 million people die each year from cardiovascular diseases, an estimated 31% of deaths globally. Cardiovascular disease is the name for a group of conditions in regards of the heart and blood vessels and this include hypertension (high blood pressure), coronary heart disease (heart attack), cerebrovascular disease (stroke), peripheral vascular disease, heart failure, rheumatic heart disease, congenital heart disease, cardiomyopathies.

# data[].attributes.body
No. 1 Killer in the World

# data[].attributes.body
Regardless the implementation of new technology advances in cardiovascular diseases the outcomes have not been equitable because the challenges that cardiovascular medicine is now facing with the impact of disparate cardiovascular issues such as the function of race, ethnicity, gender, and socioeconomic status.

# data[].attributes.body
Must of the countries around the world are facing the same issues with the increase of CVD’s for developing countries the situation is even worse because of the limited resources that some have.

# data[].attributes.body
Finding solution to the increase of CVD is very important to different organization around the world. Trying different method of prevention and the implementation of new technology are also priorities for many countries around the world.  The Prevention Impacts Simulation Model (PRISM) projects the multiyear impacts of 22 different interventions aimed at reducing risk of cardiovascular disease. PRISM is a program that is aimed at reducing risks for and other chronic conditions and diseases; is a model that simulates the multiyear impacts of a wide variety of interventions aimed at reducing risks for CVD. PRISM is used to prevent and determine risk factors and consequences of cardiovascular diseases and has been created to deal with population health that has been developed over the past decade using the system dynamics modeling approach.

# data[].attributes.attachment_link.title
Cardiovascular Disease Around the World (BIOM4180)

# data[].attributes.body
Innovation in technology and clinical trials are the future of cardiovascular diseases and possible the solution of the increase on CVD. Developing this program is expensive, and many countries cannot research as much as other developed countries. The push for innovative, pragmatic RCTs started with the need for less expensive, more generalizable answers to questions that occur in day-to-day clinical care settings and guide clinical practice.

# data[].attributes.body
In summary, cardiovascular diseases are increasing daily and are taking the lives of millions of people around the world. This is a health global problem that is affecting developed countries and also developing countries without finding a solution to it. Why the increase of CVD and how to solve the issue are the main questioners that many organizations around the world are facing.

# data[].attributes.headline
Why Is the Rate of CVD Increasing in The Developing World?

# data[].attributes.subject
Why Is the Rate of CVD Increasing in The Developing World?

# data[].attributes.body
CVD is of greater burden in the developing countries (countries with developing economies) than it is in developed countries (countries with advanced, industrial economies); the problem of CVD in the developing countries has risen dramatically in the last 50 years and is expected to continue to growth. The first is “modernization” of the developing world such as unhealthy diet, sedentary lifestyle, and tobacco uses; which has led to increased exposure to known risk factors for CVD. The second is a “modern epidemiological transition.” Efforts to combat nutritional, perinatal, and infectious diseases in the developing world have allowed many more patients to survive to middle and old age, increasing the number of patients at risk for CVD. Patients who are no longer dying from infectious disease or starvation are now living long enough to develop.